From 2 to 4 February, members of the CRMSB team (Université de Bordeaux) travelled to Toulouse to work with our partner TBI on the development of custom-made biochips, a key tool for the next phase of the ABCardionostics project.
These biochips are designed to host and test scFv-Fc antibodies developed within the project, enabling the screening of candidates that can specifically recognise different monocyte and macrophage populations involved in atherosclerosis. This work makes part of the WP4 of the project, which aim to identify highly selective antibodies for diagnostic imaging and therapeutic targeting.
During this working session, the teams focused on printing biomarker proteins from atherosclerotic plaques onto functionalized glass slides using a robotic system. These biomarkers were then incubated with various antibodies, and interactions were detected using a fluorescent secondary antibody. These biochips will allow our researchers to evaluate how well the antibodies bind to their intended cellular targets, paving the way for more advanced testing.
The visit brought together:
- Dr. Emmanuelle Trevisiol (TBI)
- Yaëlle Guiberteau (PhD student in bioinformatics, TBI, working closely with CRMSB team)
- Dr. Gisèle Clofent Sanchez (CRMSB, ABCardionostics’s coordinator)
- Dr. Marie-Josée Jacobin-Valat (CRMSB)
- Lidwine Trouilh (TBI GeT-Biopuces platform)
This hands-on collaboration marks an important milestone, ensuring that the experimental tools are ready for the next stages of antibody screening and functional validation.
We thank TBI for their close cooperation and look forward to the next steps in this exciting phase of the project.
